ADHD is the most common neurodevelopmental disorder diagnosed in children. The number of and use of approved medications for ADHD has increased over the past four decades (Steingard et al., 2019). The most commonly prescribed medications include methylphenidate and amphetamine stimulant classes, with the former recommended as the first line of treatment in children and adolescents (Cortese et al., 2018; Cortese, 2020). While stimulant medications can quickly reduce ADHD symptoms and improve behavioral and psychosocial functioning in many children with ADHD, a substantial proportion of affected children do not respond to stimulants (25-35%; Pelham et al., 1999; Stein et al., 2011), and long-term adherence or continuation is poor. Moreover, a significant percentage demonstrate preferential response to one stimulant class over another (∼40%; Arnold, 2000; Stein et al., 2011) and as a result, treatment guidelines suggest trying the alternative stimulant class in cases of non-response (Pliszka and Issues, 2007). Despite increasing interest in precision medicine approaches, as yet no evidence-based guidelines exist to direct providers toward a specific treatment for a particular child (Owens et al., 2003). As a result, a trial-and-error clinical approach has been maintained. This can lead to premature termination of titration trials, lack of dose optimization, patient dissatisfaction, and prolonged functional impairment.

Aperiodic spectral slope, also referred to as the 1/f distribution (where f is derived from the shape of the power spectral density S[f]), neural pink noise, and scale-free dynamics (He et al., 2010; Voytek et al., 2015; Donoghue et al., 2020a), is an index of spontaneous intrinsic brain activity measured with electroencephalography (EEG). Similar to a traditional spectral power distribution, the aperiodic slope can be illustrated as a distribution of oscillatory power across a range of frequencies; however, unlike traditional spectral power distributions, the aperiodic slope captures background activity absent of periodic peaks in a particular frequency range, such as the dominant alpha peak (Donoghue et al., 2020a). The steepness of the aperiodic slope is quantified by the aperiodic exponent (i.e., the X in 1/f^x). Greater aperiodic exponent reflects increased excitatory signal and engagement of global neural populations, while flatter slope reflects a shift toward inhibitory currents and local neural networks (Waschke et al., 2019). Thus, aperiodic activity potentially reflects a balance of segregation and integration of neural information across space and time. To this extent, aperiodic slope may be thought of as measure of bottom-up neurocognitive processes that influence basic sensory processing as well as higher order stimulus categorization and cognitive control.

Individual variation in aperiodic spectral slope have been linked to demographic and developmental differences. The aperiodic exponent decreases (i.e., becomes flatter) with age across the lifespan (Cellier et al., 2021; McSweeney et al., 2021; Pathania et al., 2022). Adolescent males have greater aperiodic exponents than females (McSweeney et al., 2021). Among elderly individuals, reduced aperiodic exponent is associated with greater cognitive decline (Pathania et al., 2022). Several studies have reported that children and adolescents with ADHD have reduced aperiodic exponent compared to same age controls (Arnett et al., in press; Ostlund et al., 2021), although the opposite effect may be true for preschool aged children (Robertson et al., 2019). There is emerging evidence that stimulant medication moderates the aperiodic exponent. Pertermann et al. (2019) found that the aperiodic exponents of school aged children with ADHD increased following optimized methylphenidate treatment, and this difference was correlated with improved behavioral performance. Interestingly, two studies in which the participants abstained from medication prior to the EEG also found an effect of medication history on aperiodic slope. Robertson et al. (2019) reported that preschool aged children with a history of stimulant use had relatively normalized aperiodic slope compared to controls. In contrast, our group found that children who were normally medicated for ADHD had more extreme flattening of aperiodic slope, although we hypothesized that this may be due to higher symptom severity in this sample (Arnett et al., in press). Finally, Ostlund et al. (2021) did not find an association between stimulant history and aperiodic exponent. To our knowledge, no study to date has investigated whether aperiodic spectral slope differs between stimulant responders and non-responders.

In contrast to the aperiodic slope, there is a large literature documenting attenuated amplitude of the P300 event related potential (ERP) component among children and adults with ADHD (Barry et al., 2003). In particular, individuals with ADHD show reduced amplitude of an early subcomponent of the P300 when presented with salient or novel stimuli, such as in the context of an oddball paradigm. Oddball tasks vary frequent presentation of a repeated stimulus (standard) with infrequent presentation of slightly different (deviant) and/or highly original (novel) stimuli (Goldstein et al., 2002). This novelty P3a component is generated by excitation of fronto-striatal neural populations involved in auditory or visual stimulus orientation and evaluation (Polich, 2007). Fronto-striatal neural circuitries are modulated by catecholamine neurotransmitters, particularly dopamine. Accordingly, P3a amplitude has been shown to increase to normal levels following administration of stimulant medications (Peisch et al., 2021), which are dopamine agonists. P3a amplitude is reduced in clinical samples with low dopamine levels, such as Parkinson’s Disease (Solís-Vivanco et al., 2015). Therefore, attenuated novelty P3a amplitude in ADHD is thought to reflect abnormal top-down allocation of cognitive resources during stimulus processing possibly via reduced integrity of the fronto-striatal cortical networks, and/or reduced excitatory synaptic capacity.

A small body of literature has reported associations among methylphenidate treatment, behavioral improvement, and increased amplitude of the novelty P3a or related components, among children and adolescents with ADHD. For example, Dolu et al. (2019) found decreased ADHD symptom severity and increased novelty P3 amplitude among school-aged children following methylphenidate administration. Similarly, Hermens et al. (2005) reported that methylphenidate was associated with increased P3 amplitude and enhanced task performance during an auditory oddball task with adolescents. Lopez et al. (2004) reported improved Stroop task performance and increased visual novelty P3 amplitude in children following methylphenidate treatment. Very few studies have directly investigated whether ERP components predict behavioral response to methylphenidate or other stimulant medications. Ogrim and colleagues (Ogrim et al., 2014; Ogrim et al., 2016; Ogrim and Kropotov, 2019) have repeatedly found that attenuated pre-treatment P3 amplitude during a cued go-no-go task is predictive of positive behavioral response to methylphenidate or dexamphetamine stimulants. In contrast, Sangal and Sangal (2006) found response to methylphenidate was associated with greater amplitude of the late auditory (but not visual) P300 component with weak sensitivity (65%) and specificity (67%). This group did not find ERP differences associated with response to atomoxetine.

The current study tests the hypothesis that two electrophysiological indices of neurocognitive functioning will be associated with methylphenidate response in children with ADHD. First, we hypothesize that the aperiodic exponent and novelty P3a amplitude are potential biomarkers of individual response to methylphenidate among school age children with ADHD. Secondly, we hypothesize that children with evidence of both bottom-up and top-down cognitive dysregulation (i.e., flat aperiodic slope and attenuated P3a amplitude, respectively) will show greater response to methylphenidate, relative to children with normal neurocognitive functioning in one or both measures.

Sample demographics are described in Table 1. ADHD and control subjects did not differ on age, proportion of non-White participants, or proportion of females; however, the control group had a significantly higher abbreviated IQ than the ADHD group, as measured with the two-subtest version of the Wechsler Abbreviated Scale of Intelligence, 2nd Edition (WASI-II) (Wechsler, 2011). Demographic differences across the methylphenidate response groups (controls, responders and non-responders) were also examined. Responders were more likely to be described as white by their caregivers (χ²[2] = 6.51, p = 0.039). Response groups did not differ on age (F[2,52] = 1.48, p = 0.236) or proportion of females (χ²[2] = 1.54, p = 0.462). Responders and non-responders did not differ on IQ (p = 0.967). Thus, only the binomial self-identified race variable (white versus non-white) was included in subsequent analyses.

Results of the multinomial logistic regression model are reported in Table 2. As expected, methylphenidate responders showed attenuated P3a amplitude relative to controls (Figure 1B), while non-responders did not.

Contrary to our predictions, the opposite pattern emerged for aperiodic slope (Figure 2). Methylphenidate non-responders had flatter aperiodic slope than did controls, while the aperiodic exponent did not differ between responders and controls (although the effect approached significance in the expected direction). Finally, children described as white by their caregivers were more likely to be characterized as methylphenidate responders.

Finally, we examined the ability for the combined P3a and aperiodic slope indices to predict responder group membership. The average AUC was 0.79 (95% CI: 0.50 – 0.99), with an optimized sensitivity/specificity of 0.71 and 0.70, respectively.

Aperiodic spectral slope and novelty P3a amplitude measure distinct neural processes, with the former reflecting global patterns of intrinsic activity at rest and the latter representing time-locked activation of fronto-striatal neuronal populations. In the current study, the combination of these measures achieved moderate to high accuracy for predicting retrospective report of response to methylphenidate in a small sample of children with ADHD. More specifically, methylphenidate responders and non-responders showed opposing patterns of neural atypicality, wherein responders were characterized by attenuated ERP amplitude and non-responders characterized by reduced aperiodic exponent.

These preliminary results indicate that methylphenidate, which increases catecholamine availability in the synapse, may be more effective for children whose blunted P3a amplitudes suggest reduced excitation of neuronal populations in the frontal-striatal cortices. This is consistent with a substantial body of research demonstrating that methylphenidate enhances (i.e., “normalizes”) P3a amplitude among children with ADHD (Peisch et al., 2021). The implication is that increased availability of catecholamine neurotransmitters normalizes the functioning of the fronto-striatal networks, possibly by facilitating excitation of larger neural populations.

In contrast, our results suggest that methylphenidate may be less effective for children with intact P3a amplitudes and flatter aperiodic slope. The aperiodic slope is a measure of the balance of slower versus faster background neural oscillations. While slower oscillations are generated by larger, coordinated global neuronal populations, faster oscillations generally reflect activity in smaller, local neural networks. Thus, the balance of slow and fast aperiodic oscillations represents an intrinsic “self-tuning” by the brain that supports flexible and efficient neuronal activation in response to periodic environmental elements. In a dark room at rest, as in the current study, the brain is expected to show a greater emphasis toward engagement of long-range, global networks (i.e., steeper aperiodic slope), while in an environment with more visual or auditory input, the emphasis shifts toward involvement of smaller, more segregated networks (i.e., flatter aperiodic spectral slope). Dynamic shifts of this balance in response to environmental conditions, which have previously been demonstrated to be atypical in ADHD populations (Arnett et al., 2021), facilitate efficient processing of environmental input.

If flatter aperiodic slope is a mechanism contributing to ADHD symptoms among non-responders, then our study may indicate that increased availability of catecholamines is not as effective at normalizing intrinsic activity patterns in the brain. However, results of a prior study were inconsistent with this theory, in that they found methylphenidate treatment did indeed increase the aperiodic exponent in children with ADHD (Pertermann et al., 2019). Methodological differences may explain these divergent conclusions. First, Pertermann et al. (2019) used a method of calculating the aperiodic slope that Ostlund et al. (2021) have reported results in different values than those produced by FOOOF (the method used in the current study). Second, the aperiodic slope calculated by Pertermann et al. (2019) was measured while children were performing a go-no-go task, which in healthy brains, would be expected to lead to flattening of the aperiodic slope relative to our lights-off condition.

Our findings are consistent with prior studies reporting that faster frontal alpha peak frequency in male children and adolescents with ADHD is associated with a history of improved behavioral response to MPH (Arns, 2012; Voetterl et al., 2022). The alpha peak is a periodic feature of the power spectral density distribution generated by the thalamus (Hughes and Crunelli, 2005). Thus, like the P3a, alpha bursts reflect time limited neuronal spiking rather than background oscillatory activity. In future work, it will be important to evaluate the predictive power of multiple periodic and aperiodic signals using a prospective study design.

The current results must be interpreted with caution, however, given the small sample size and retrospective nature of our methylphenidate responder categorization. Prospective studies involving treatment naïve children and consistent optimization of methylphenidate dosing will be necessary to validate our findings. Moreover, while we hypothesize that behavioral effects of methylphenidate are correlated with change in our neurobiological markers, we were not able to re-test these children while on medications as part of the current study. Thus, we cannot confirm that these neural markers of treatment response represent a neurobiological mechanism for the individual child’s ADHD symptoms. Moreover, although all children abstained from prescribed ADHD medications for 48 hours (or longer, for non-stimulants) prior to the EEG, we cannot rule out the possibility that prior stimulant use moderated these neural signatures, a finding that has been suggested in previous work (Pertermann et al., 2019; Robertson et al., 2019). Finally, our analyses were not adequately powered to investigate the potential contribution of co-existing symptomology, such as internalizing and externalizing symptoms. Possibly, inclusion of multimethod indicators (e.g., psychiatric, cognitive, and neural) would improve the predictive accuracy of these models in future research.

Measurement of brain activity using electroencephalography is feasible and thus presents as a strong candidate technique for measuring individual indicators of treatment response. The results of our preliminary work indicate at least two distinct electrophysiological markers of ADHD symptoms were associated with divergent responses to methylphenidate. These findings have potential to improve delivery of precision medicine care for children with ADHD, as well as inform our understanding of the neurobiological mechanisms contributing to the broader ADHD phenotype.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by University of Washington Institutional Review Board. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AA wrote the first draft of the manuscript, contributed to study design, conceptualization and data collection, and ran statistical analyses. TR contributed to conceptualization and data collection and reviewed the final manuscript. MS contributed to study design and conceptualization, contributed to manuscript drafts, and reviewed the final manuscript. All authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.